Oncology Research Open Access Editors-in-Chief: Edward Chu, Enrico Mini
Home Oncology Research

Overview

  • Oncology Research is committed to publishing high-quality, innovative research that is focused on the entire range of basic, translational, and clinical cancer research, with a particular interest in cancer therapeutics.Specific areas of interest include but are not limited to: identification of potential targets for cancers and the exploration of novel molecular mechanisms of tumorigenesis and metastasis; development of novel small molecules and targeted therapies;mechanisms of drug sensitivity; mechanisms of cellular drug resistance; biomarkers of response and/or resistance; novel experimental model systems and technologies relating to cancer therapeutics; pharmacogenetics and pharmacogenomics; personalized medicine; cancer stem cell; immunotherapy and clinical immunology; gene therapy; and radiobiology and novel approaches to radiation therapy either alone or in combination with chemotherapy. For studies that investigate the role of non-coding RNAs as regulators of cellular gene expression, it will be important for more in-depth mechanistic studies to be conducted that confirm their biological activity and their potential effect as mediators of chemosensitivity. The journal also embraces preclinical studies that are focused on drug design, chemical biology, and drug screening. In addition, submissions that investigate the potential role of herbal/botanical medicines in preclinical and clinical cancer therapy are welcomed; however, it will be important to document that these medicines are of high quality, with confirmation of batch-to-batch consistency. In addition to original peer-reviewed articles, the journal also welcomes timely reviews, case reports, editorials, analyses, letters and other types of manuscripts.

    View Aims and Scope

  • Editors-in-Chief: Edward Chu, Enrico Mini

    View Editorial Board

  • Tech Science Press

    View Publisher Infomation

  • 2.0

    Impact Factor (2023)

  • 4.4

    CiteScore (2023)